Within the propensity-matched patients, 20.3%, 2.9%, and 4.4% of hyperoncotic albumin-exposed patients experienced stages 1, 2, and 3 of acute kidney injury, as compared to 19.6%, 2.5%, and 3.0% of control patients (Fig. 3). This evidence concerns the gene ALB and acute kidney injury.